205 related articles for article (PubMed ID: 36143954)
1. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites.
Yokoyama K; Fukuda H; Yamauchi R; Higashi M; Miyayama T; Higashi T; Uchida Y; Shibata K; Tsuchiya N; Fukunaga A; Umeda K; Takata K; Tanaka T; Shakado S; Sakisaka S; Hirai F
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143954
[TBL] [Abstract][Full Text] [Related]
2. Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.
Suzuki H; Sezaki H; Suzuki F; Kasuya K; Sano T; Fujiyama S; Kawamura Y; Hosaka T; Akuta N; Saitoh S; Kobayashi M; Arase Y; Ikeda K; Suzuki Y; Kumada H
Hepatol Res; 2019 Dec; 49(12):1406-1413. PubMed ID: 31347756
[TBL] [Abstract][Full Text] [Related]
3. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy.
Ishikawa T; Endo S; Imai M; Azumi M; Nozawa Y; Sano T; Iwanaga A; Honma T; Yoshida T
Intern Med; 2020; 59(20):2465-2469. PubMed ID: 33055469
[TBL] [Abstract][Full Text] [Related]
4. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species.
Yukawa-Muto Y; Kamiya T; Fujii H; Mori H; Toyoda A; Sato I; Konishi Y; Hirayama A; Hara E; Fukuda S; Kawada N; Ohtani N
Hepatol Commun; 2022 Aug; 6(8):2090-2104. PubMed ID: 35429147
[TBL] [Abstract][Full Text] [Related]
5. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
Glal KAM; Abd-Elsalam SM; Mostafa TM
J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.
Lv XY; Ding HG; Zheng JF; Fan CL; Li L
World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585
[TBL] [Abstract][Full Text] [Related]
7. [Rifaximin improves clinical symptoms and short-term survival in cirrhotic patients with refractory type ascites].
Wang Z; Hou W; Zhang W; Wu HX; Zheng SJ; Hu ZJ
Zhonghua Gan Zang Bing Za Zhi; 2022 Nov; 30(11):1170-1174. PubMed ID: 36891693
[No Abstract] [Full Text] [Related]
8. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Tatsumi R; Suii H; Yamaguchi M; Arakawa T; Nakajima T; Kuwata Y; Toyota J; Hige S
Intern Med; 2021 May; 60(10):1501-1507. PubMed ID: 33361677
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Hanafy AS; Hassaneen AM
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1455-1461. PubMed ID: 27622998
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
Nakai M; Suda G; Ogawa K; Yoshida S; Hosoda S; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Ohara M; Sho T; Morikawa K; Sakamoto N
PLoS One; 2022; 17(7):e0270786. PubMed ID: 35776720
[TBL] [Abstract][Full Text] [Related]
11. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
Eriksen PL; Djernes L; Vilstrup H; Ott P
J Hepatol; 2023 Aug; 79(2):340-348. PubMed ID: 37061198
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.
Fujiwara Y; Suzuki K; Yusa K; Eizuka M; Miura M; Watanabe Y; Takahashi H; Takikawa Y
Intern Med; 2021; 60(7):1027-1033. PubMed ID: 33790139
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
16. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
Kawaratani H; Kondo Y; Tatsumi R; Kawabe N; Tanabe N; Sakamaki A; Okumoto K; Uchida Y; Endo K; Kawaguchi T; Oikawa T; Ishizu Y; Hige S; Takami T; Terai S; Ueno Y; Mochida S; Takikawa Y; Torimura T; Matsuura T; Ishigami M; Koike K; Yoshiji H
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329897
[TBL] [Abstract][Full Text] [Related]
18. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
19. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
